High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
09 06 2020
Historique:
received: 30 07 2019
accepted: 15 04 2020
entrez: 4 6 2020
pubmed: 4 6 2020
medline: 11 5 2021
Statut: ppublish

Résumé

Clonal hematopoiesis of indeterminate potential (CHIP) is predictive of hematological cancers and cardiovascular diseases, but the etiology of CHIP initiation and clonal expansion is unknown. Several lines of evidence suggest that proinflammatory cytokines may favor mutated hematopoietic stem cell expansion. To investigate the potential link between inflammation and CHIP, we performed targeted deep sequencing of 11 genes previously implicated in CHIP in 1887 subjects aged >70 years from the Montreal Heart Institute Biobank, of which 1359 had prior coronary artery disease (CAD), and 528 controls did not. We assessed association of CHIP with log transformed high-sensitivity C-reactive protein (hs-CRP), a validated biomarker of inflammation. CHIP was identified in 427 of the 1887 subjects (22.6%). CHIP mutations were more frequently identified in DNMT3A (11.6%) and TET2 (6.1%), with a higher proportion of TET2 mutations occurring in controls than in patients with CAD (9.0% vs 4.9%, P < .001). CHIP carriers had 21% higher hs-CRP levels compared with their noncarrier counterparts (eβ = 1.21, 95% confidence interval [CI]: 1.08 to 1.36; P = .001). A similar effect was observed in the subgroup of patients with known CAD (eβ = 1.22, 95% CI: 1.06 to 1.41; P = .005). These findings confirm the association between inflammation and CHIP. This association may open investigational avenues aimed at documenting mechanisms linking inflammation to clonal progression and ultimately supports prevention interventions to attenuate CHIP's impact on cardiovascular disease and cancer.

Identifiants

pubmed: 32492156
pii: S2473-9529(20)31270-2
doi: 10.1182/bloodadvances.2019000770
pmc: PMC7284088
doi:

Substances chimiques

Angiotensin Receptor Antagonists 0
Angiotensin-Converting Enzyme Inhibitors 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2430-2438

Subventions

Organisme : CIHR
Pays : Canada

Informations de copyright

© 2020 by The American Society of Hematology.

Références

Blood. 2020 Jan 23;135(4):269-273
pubmed: 31697828
N Engl J Med. 2014 Dec 25;371(26):2477-87
pubmed: 25426838
Exp Hematol. 2020 Mar;83:2-11
pubmed: 32001340
Haematologica. 2019 Nov 7;:
pubmed: 31699791
Blood. 2017 Aug 10;130(6):742-752
pubmed: 28483762
Blood. 1996 Jul 1;88(1):59-65
pubmed: 8704202
Biochem Biophys Res Commun. 1988 Aug 30;155(1):112-7
pubmed: 3261980
Blood. 2016 Dec 8;128(23):2671-2682
pubmed: 27621307
Blood. 1994 Feb 15;83(4):931-8
pubmed: 8111064
N Engl J Med. 2014 Dec 25;371(26):2488-98
pubmed: 25426837
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
Nat Commun. 2016 Aug 22;7:12484
pubmed: 27546487
Circ Cardiovasc Genet. 2016 Aug;9(4):340-8
pubmed: 27418594
Nature. 2018 May;557(7706):580-584
pubmed: 29769727
Circ Res. 2016 Jan 8;118(1):145-56
pubmed: 26837745
Blood. 2020 Jan 23;135(4):261-268
pubmed: 31697811
Nature. 2015 Sep 17;525(7569):389-393
pubmed: 26287468
J Biol Chem. 1979 Jan 25;254(2):489-502
pubmed: 762075
Exp Hematol. 2020 Mar;83:66-73
pubmed: 31893524
Science. 2017 Feb 24;355(6327):842-847
pubmed: 28104796
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Blood Adv. 2019 Aug 27;3(16):2482-2486
pubmed: 31434682
JAMA Cardiol. 2019 Jan 1;4(1):25-33
pubmed: 30566180
N Engl J Med. 2017 Jul 13;377(2):111-121
pubmed: 28636844
Exp Hematol. 2019 Dec;80:36-41.e3
pubmed: 31812712
J Am Coll Cardiol. 2018 Feb 27;71(8):875-886
pubmed: 29471939
Blood. 2013 Mar 7;121(10):1824-38
pubmed: 23299311
Nat Med. 2014 Dec;20(12):1472-8
pubmed: 25326804
BMJ. 2001 Jan 6;322(7277):4-5
pubmed: 11141130
Exp Hematol. 2018 Mar;59:60-65
pubmed: 29195897
Stem Cells. 2018 Sep;36(9):1287-1294
pubmed: 29883022
Circulation. 2020 Jan 14;141(2):124-131
pubmed: 31707836
Medicine (Baltimore). 2019 May;98(22):e15844
pubmed: 31145332
J Exp Med. 1930 Sep 30;52(4):561-71
pubmed: 19869788
N Engl J Med. 2000 Mar 23;342(12):836-43
pubmed: 10733371
Adv Exp Med Biol. 2011;691:141-50
pubmed: 21153318
Blood. 2017 Aug 10;130(6):753-762
pubmed: 28655780
Nature. 2018 Jul;559(7714):400-404
pubmed: 29988082
Cell Stem Cell. 2018 Dec 6;23(6):833-849.e5
pubmed: 30526882
Clin Chem. 2001 Mar;47(3):403-11
pubmed: 11238289
Lancet. 2017 Oct 21;390(10105):1833-1842
pubmed: 28855077
Nat Genet. 2012 Nov;44(11):1179-81
pubmed: 23001125
Trends Endocrinol Metab. 2017 Mar;28(3):199-212
pubmed: 27789101
Blood. 2018 Jul 19;132(3):277-280
pubmed: 29764839
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582

Auteurs

Lambert Busque (L)

Research Center.
Hematology Division, Hôpital Maisonneuve-Rosemont.
Department of Medicine, Université de Montréal, Montreal, Canada.

Maxine Sun (M)

Department of Medicine, Université de Montréal, Montreal, Canada.
Beaulieu-Saucier Pharmacogenomics Center, Montreal Heart Institute, Montreal, Canada.

Manuel Buscarlet (M)

Research Center.

Sami Ayachi (S)

Research Center.
Department of Medicine, Université de Montréal, Montreal, Canada.

Yassamin Feroz Zada (Y)

Beaulieu-Saucier Pharmacogenomics Center, Montreal Heart Institute, Montreal, Canada.

Sylvie Provost (S)

Beaulieu-Saucier Pharmacogenomics Center, Montreal Heart Institute, Montreal, Canada.

Vincent Bourgoin (V)

Research Center.

Luigina Mollica (L)

Research Center.
Hematology Division, Hôpital Maisonneuve-Rosemont.
Department of Medicine, Université de Montréal, Montreal, Canada.

Marlies Meisel (M)

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA; and.

Reinhard Hinterleitner (R)

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA; and.

Bana Jabri (B)

Department of Medicine, University of Chicago, Chicago, IL.

Marie-Pierre Dubé (MP)

Department of Medicine, Université de Montréal, Montreal, Canada.
Beaulieu-Saucier Pharmacogenomics Center, Montreal Heart Institute, Montreal, Canada.

Jean-Claude Tardif (JC)

Department of Medicine, Université de Montréal, Montreal, Canada.
Beaulieu-Saucier Pharmacogenomics Center, Montreal Heart Institute, Montreal, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH